Literature DB >> 20667858

Patient perception of dyskinesia in Parkinson's disease.

S W Hung1, G M Adeli, T Arenovich, S H Fox, A E Lang.   

Abstract

OBJECTIVE: To evaluate the perception of patients with Parkinson's disease (PD) regarding dyskinesia.
DESIGN: Multicentre survey.
SETTING: Tertiary referral centres. PATIENTS: Patients with PD participated in a survey: those not on dopaminergic medications (group I), those on dopaminergic medications without dyskinesia (group II) and those on dopaminergic medications with dyskinesia (group III). INTERVENTION: After a short standardised description and explanation of dyskinesia was provided, patients were asked about the nature and source of prior knowledge of dyskinesia. They were then asked about their perceptions of dyskinesia. Patients in group III were also asked about the duration, the severity of dyskinesia and whether their perception of this problem had changed since its appearance. MAIN OUTCOME MEASURES: Level of concern regarding dyskinesia and whether their perception of dyskinesia would have changed their preference of treatment. Results 259 PD patients completed the survey (group I, 52; group II, 102; group III, 105). Patients with dyskinesia were significantly less concerned about dyskinesia than patients without dyskinesia and were more likely to choose dyskinesia over being parkinsonian. Patients who required fewer changes in medications because of dyskinesia were more likely to choose dyskinesia over parkinsonism.
CONCLUSION: Patients with PD experiencing dyskinesia are less likely to be concerned about dyskinesia and more likely to prefer dyskinesia over parkinsonian symptoms than patients without dyskinesia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20667858     DOI: 10.1136/jnnp.2009.173286

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

Review 1.  Integrating Patient Concerns into Parkinson's Disease Management.

Authors:  Shen-Yang Lim; Ai Huey Tan; Susan H Fox; Andrew H Evans; Soon Chai Low
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 2.  Dyskinesias and levodopa therapy: why wait?

Authors:  Michele Matarazzo; Alexandra Perez-Soriano; A Jon Stoessl
Journal:  J Neural Transm (Vienna)       Date:  2018-02-10       Impact factor: 3.575

3.  Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice.

Authors:  Li Li; Guozhen Qiu; Shengyuan Ding; Fu-Ming Zhou
Journal:  Brain Res       Date:  2012-11-15       Impact factor: 3.252

4.  Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.

Authors:  L Li; F-M Zhou
Journal:  Neuroscience       Date:  2013-01-26       Impact factor: 3.590

5.  Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx).

Authors:  Jori E Fleisher; Nabila A Dahodwala; Sharon X Xie; Mark Mayo; Daniel Weintraub; Joshua Chodosh; Judy A Shea
Journal:  J Parkinsons Dis       Date:  2016-04-02       Impact factor: 5.568

6.  Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-11

7.  Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys.

Authors:  Garikoitz Azkona; Irene Marcilla; Rakel López de Maturana; Amaya Sousa; Esther Pérez-Navarro; Maria-Rosario Luquin; Rosario Sanchez-Pernaute
Journal:  Mol Neurobiol       Date:  2014-04-05       Impact factor: 5.590

8.  The Neuropsychiatric Fluctuations Scale for Parkinson's Disease: A Pilot Study.

Authors:  Emmanuelle Schmitt; Paul Krack; Anna Castrioto; Helene Klinger; Amelie Bichon; Eugénie Lhommée; Pierre Pelissier; Valerie Fraix; Stephane Thobois; Elena Moro; Pablo Martinez-Martin
Journal:  Mov Disord Clin Pract       Date:  2018-03-23

Review 9.  Technology in Parkinson's disease: Challenges and opportunities.

Authors:  Alberto J Espay; Paolo Bonato; Fatta B Nahab; Walter Maetzler; John M Dean; Jochen Klucken; Bjoern M Eskofier; Aristide Merola; Fay Horak; Anthony E Lang; Ralf Reilmann; Joe Giuffrida; Alice Nieuwboer; Malcolm Horne; Max A Little; Irene Litvan; Tanya Simuni; E Ray Dorsey; Michelle A Burack; Ken Kubota; Anita Kamondi; Catarina Godinho; Jean-Francois Daneault; Georgia Mitsi; Lothar Krinke; Jeffery M Hausdorff; Bastiaan R Bloem; Spyros Papapetropoulos
Journal:  Mov Disord       Date:  2016-04-29       Impact factor: 10.338

Review 10.  Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?

Authors:  Jean-François Daneault; Benoit Carignan; Abbas F Sadikot; Michel Panisset; Christian Duval
Journal:  BMC Med       Date:  2013-03-20       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.